U0126 reverses Ki-ras-mediated transformation by blocking both mitogen- activated protein kinase and p70 S6 kinase pathways

Cancer Research

Volumn 60, Issue 8, 2000, Pages 2104-2107

  Fukazawa, Hidesuke ^a   Uehara, Yoshimasa ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MITOGEN ACTIVATED PROTEIN KINASE; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL KILLING; ENZYME ACTIVATION; ENZYME ACTIVITY; IMMUNOBLOTTING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; BUTADIENES; CELL LINE, TRANSFORMED; CELL SIZE; CELL TRANSFORMATION, NEOPLASTIC; CONTACT INHIBITION; DRUG SYNERGISM; ENZYME ACTIVATION; FIBROBLASTS; FLAVONOIDS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; ONCOGENE PROTEIN P21(RAS); PHENOTYPE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS;

EID: 0034655220     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Macpherson, I., and Montagnier, L. Agar suspension culture for the selective assay of cells transformed by polyoma virus. Virology, 23: 291-294, 1964.
2. Shin, S., Freedman, V. H., Risser, R., and Pollack, R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro, Proc. Natl. Acad. Sci. USA, 72: 4435-4439, 1975.
3. Fukazawa, H., Mizuno, S., and Uehara, Y. A microplate assay for quantitation of anchorage-independent growth of transformed cells. Anal. Biochem., 228: 83-90, 1995.
4. Fukazawa, H., Nakano, S., Mizuno, S., and Uehara, Y. Inhibitors of anchorage-independent growth affect the growth of transformed cells on poly(2-hydroxyethyl methacrylate)-coated surfaces. Int. J. Cancer, 67: 876-882, 1996.
5. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, R. L., Scherle, P. A., and Trzaskos, J. M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem., 273: 18623-18632, 1998.
6. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA, 92: 7686-7689, 1995.
7. Kuo, C. J., Chung, J., Fiorentino, D. F., Flanagan, W. M., Blenis, J., and Crabtree, G.R. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature (Lond.), 358: 70-73, 1992.
8. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem., 270: 27489-27494, 1995.
9. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., and Der, C. J. Increasing complexity of Ras signaling. Oncogene, 17: 1395-1413, 1998.
10. Price, D. J., Grove, J. R., Calvo, V., Avruch, J., and Bieret, B. E. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science (Washington DC), 257: 973-977, 1992.
11. Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., and Schreiber, S. L. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature (Lond.), 377: 441-446, 1995.
12. Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., and Abraham, R. T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem., 270: 815-822, 1995.
13. Penuel, E., and Martin, G. S. Transformation by v-Src: Ras-MAPK and P13K-mTOR mediate parallel pathways. Mol. Biol. Cell. 10: 1693-1703, 1999.
14. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., and Jove, R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol., 18: 2545-2552, 1998.
15. Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., and Darnell, J. E., Jr. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol., 18: 2553-2558, 1998.
16. Bos, J. I., ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
17. Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., and Kohno, M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene, 18: 813-822, 1999.
18. Sivaraman, V. S., Wang, H., Nuovo, G. J., and Malbon, C. C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest., 99: 1478-1483, 1997.
19. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., Leopold, W. R., and Saltiel, A. R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat.Med., 5: 810-816, 1999.
20. Oliff, A. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim. Biophys. Acta, 1423: C19-C30, 1999.